## **POLYPEPTIDE GROUP AG CHF0.01**

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock



## **Company Profile**

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.							
	20	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity	
Current assets	303,651,000		248,405,000		343,596,000		
Common stock capital		280,000		298,000		312,000	
Fixed assets	337,013,000		320,133,000		272,957,000		
Equity capital of a company		354,435,000		416,372,000		436,402,000	
Cash and cash equivalents	88,980,000		37,055,000		141,231,000		
Accrued liabilities		24,879,000		28,746,000		45,123,000	
Other assets	-		-		-		
Current liabilities		164,050,000		94,843,000		107,720,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		122,178,000		57,322,000		72,431,000	
Different income		-		-		-	
Other liabilities		30,730,000		9,291,000		10,674,000	
Total assets	640,664,000	640,664,000	568,538,000	568,538,000	616,554,000	616,554,000	

Balance notes			
	2023	2022	202
Accounting standard	IFRS	IFRS	IFR
Employees	1,273	1,219	1,10
Equity ratio	55.32%	73.24%	70.78%
Debt-equity ratio	80.76%	36.55%	41.289
Others			
	2023	2022	202
Tax Expense Rate	11.68%	-2.64%	21.049

## **POLYPEPTIDE GROUP AG CHF0.01**

ISIN: CH1110760852 WKN: 111076085 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	311,256,000	282,031,000	304,878,000
Net income	-49,976,000	7,796,000	51,069,000
EBIT	-50,766,253	11,311,020	69,807,968
Operating income before taxes	-56,585,000	7,595,000	64,674,000
Cash Flow	35,446,000	5,480,000	61,977,000
Net interest income	-7,120,000	-3,425,000	-3,344,000
Research and development expenses	1,423,000	1,247,000	1,520,000
Income taxes	-6,609,000	-200,000	13,605,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	250,937	237,448	284,193

<b>Board of Directors</b>	
Beat In-Albon	Member of the administrative board
Jane Salik	Member of the administrative board
Patrick Aebischer	Member of the administrative board
Philippe Weber	Member of the administrative board
Erik Schropp	Member of the administrative board
Peter Wilden	Chairman of the administrative boar

Members of Management Board		
Juan-José Gonzalez	Chairman of Managing Board	
Christina del Vecchio	Member of Executive Committee	
Jens Fricke	Member of Executive Committee	
Marc Augustin	Member of Executive Committee	
Neil Thompson	Member of Executive Committee	